Evaxion A/S · NASDAQ:EVAX
Evaxion A/S — Q2 2024 Earnings Presentation
21 slides from Evaxion A/S's earnings presentation, Aug 14, 2024
Slide 1: Evaxion Business Update Conference Call Q2 2024
Evaxion Business Update Conference Call Q2 2024 Christian Kanstrup, CEO Birgitte Rønø, CSO Jesper Nyegaard Nissen, COO & CFO Mads Kronborg, VP Investor Relations and Communication August 14, 2024
Slide 2: Agenda
AGENDA 1. Introduction CEO, Christian Kanstrup 2. R&D/Business Update CSO, Birgitte Rønø 3. Q2 2024 Financial Results COO & CFO, Jesper Nyegaard Nissen 4. Conclusive Remarks CEO, Christian Kanstrup 5. Q&A 2
Slide 3: Forward-Looking Statement
Forward-Looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “m
Slide 4: Key Achievements Since Last Business Update
Key Achievements Since Last Business Update • Advancing multi-partner approach • Solid interest from external parties in both our AI- Immunology platform and pipeline candidates • Several partnership discussions ongoing • Progressing the EVX-01 program • Positive and validating Phase 2 immune data p
Slide 5: Strategy Recap: Three-Pronged Business Model Based upon AI-Immunology
Strategy Recap: Three-Pronged Business Model Based upon AI-Immunology Multi-partner approach to value realization TARGETS Multi-partner approach focused around single or multiple vaccine target discovery, design and development agreements PIPELINE Own development programs for select high value progr
Slide 6: Several 2024 Milestone to Report Shortly
Several 2024 Milestone to Report Shortly Milestones Target EVX-B1 Conclusion of final MTA study with potential partner Q1 2024 AI- Mid 2024 Launch of EDEN model version 5.0 Immunology (ECCB, September) Q3 2024 EVX-B2-mRNA EVX-B2-mRNA preclinical Proof-of-Concept obtained (18th Vaccine Congress, Sept
Slide 7: R&D/Business Update
R&D/Business Update 7
Slide 8: R&D/Business Update – Conclusions
R&D/Business Update – Conclusions Pipeline Progress, EVX-01 Lead vaccine: Improvement of AI-Immunology platform: • Immune data from our ongoing EVX-01 Phase • Improved performance of key AI- 2 trial presented at ASCO in June Immunology building block, EvaxMHC presented at a computational biology con
Slide 9: Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology Platform
Pipeline: Demonstrating the Performance and Scalability of Our AI-Immunology Platform I ND I CA TI ON/ STA G E OF DE VE L OPM ENT A I MOD EL PAR TNER PAT HOG EN T A R GE T D IS CO V ER Y PR E CL IN IC AL PH A SE 1 PH A SE 2 C ANC E R VA CC IN ES Metastatic melanoma Pembrolizumab supply EVX-01 (Lipos
Slide 10: EVX-01 – Phase 2 Study Design and Milestones
EVX-01 – Phase 2 (NCT05309421) Study Design and Milestones Enrolled 17 patients with metastatic melanoma Conducted in collaboration with Merck & Co., Inc., (MSD) Primary endpoint: Change in Best Overall Response Selected secondary endpoint: T-cell response induced by EVX-01 EVX-01 Priming EVX-01 Boo
Slide 11: Encouraging Initial EVX-01 Phase 2 Trial Results presented at ASCO
Encouraging Initial EVX-01 Phase 2 Trial Results presented at ASCO Response to Vaccine Neoantigens P = 0.03 P = 0.09 Initial data from twelve patients: 2000 SFUs per 1 x 106 PBMCs • Confirm the favorable safety profile of EVX-01 1500 P = 0.03 • Neoantigen specific T-cell reactivity induced by EVX- 0
Slide 12: Neoantigen AI-Immunology Quality Score Correlates Positively with T-cell Responses
Neoantigen AI-Immunology Quality Score Correlates Positively with T-cell Responses Number of Immunogenic NeoAgs during Correlation between neoAg responses and AI- EVX-01 priming Immunology NeoAg quality scores 10 Immunogenic neoAgs: 1500 Pearson, r = 0.24 # of immunogenic neoAgs 64/90 (71%) P = 0.03
Slide 13: Upcoming 1-Year Readout will be a Key Milestone for EVX-01
Upcoming 1-Year Readout will be a Key Milestone to Support Further Clinical Development of EVX-01 Beyond Phase 2 Interim Evaluation of Further Validation of 1Y Clinical Data T-cell Responses PIONEERTM Prediction Readout • T-cell response in all • 71% of neoantigens • Further data (n=12) interim pati
Slide 14: AI-Immunology Improvement
AI-Immunology Improvement Improved Performance of Key Building Block in AI- Immunology The Adaptive Immune System Revolves Around the MHC•Peptide•TCR Interaction • Our proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology platform • Utilizing a state-of-the-art nov
Slide 15: R&D/Business Update – Summary
R&D/Business Update – Summary Pipeline Progress, EVX-01 Lead vaccine: Improvement of AI-Immunology platform: • Immune data from our ongoing EVX-01 Phase • Improved performance of key AI- 2 trial presented at ASCO in June Immunology building block, EvaxMHC presented at • On track for one-year clinica
Slide 16: Q2 2024 Financial Results
Q2 2024 Financial Results 16
Slide 17: Financials Q2 2024 Highlights
Financials Q2 2024 Highlights • Effects of 2023 cash spend optimization and organizational slimming to reflect focused strategy shows impact in the financial results • As of June 30, 2024, cash and cash equivalents were $8.0 million • We expect that our existing cash and cash equivalents, will be su
Slide 18: Q2 2024 Financial Results (Unaudited)
Financials Q2 2024 Financial Results (Unaudited) • Research and Development expenses were $5.6 million for the six months ended June 30, 2024. The decrease vs 2023 was primarily due to a decrease in employee related costs • General and Administrative expenses were $3.6 million for the six months end
Slide 19: Conclusive Remarks
Conclusive Remarks 19
Slide 20: Conclusive Remarks
Conclusive Remarks • Solid progress on the Evaxion three-pronged business model • Strong focus on advancing ongoing business development discussions • EVX-01 continues to deliver solid data, major milestone coming up at ESMO in September • Several key 2024 milestones to report out shortly 20
Slide 21: Q&A
Q&A